The aptamers market size is likely to grow at a 20.2% CAGR between 2018- 2023 reveals the new Market Research Future (MRFR) report. Aptamers, simply put, are peptide molecules or oligonucleotides which bind to target lipid, proteins, or nucleic acid molecules.
Numerous factors are adding to the aptamers market growth. Such factors, as revealed by the latest MRFR report, include increasing use in disease treatment and drug discovery, an increasing number of companies investing in the market, improvement in apatamers development technologies, and proven high diagnostic and therapeutic value of RNA aptamers with current FDA approval for the first-ever aptamers drug.
Scope of the Report
The report categorizes the aptamers market based on type, application, technology, end-users, regions, and key players. Aptamers are single-stranded, short RNA, or DNA molecules that can bind selectively to specific targets such as live cells, toxins, carbohydrates, small molecules, proteins, and molecules. Such molecules are highly versatile and used for binding targets with high selectivity and specificity.
On the contrary, strict regulations in the usage of aptamers, slow in reaching the marketplace due to regulatory hurdles, and ethical issues to use aptamers are factors that may limit the aptamers market growth over the forecast period.
Notable players profiled in the global aptamers market report include Noxxon Pharma, Vivonics, Inc., Trilink Biotechnologies, Inc., Somalogic, Inc., Neoventures Biotechnology Inc., Aptus Biotech S.L., Aptamer Solutions Ltd., Am Biotechnologies, LLC, Ophthotech Corporation, Base Pair Biotechnologies, Inc., Aptagen, LLC, and Sciences, Inc.